CA2539546C - Isoquinoline potassium channel inhibitors - Google Patents

Isoquinoline potassium channel inhibitors Download PDF

Info

Publication number
CA2539546C
CA2539546C CA2539546A CA2539546A CA2539546C CA 2539546 C CA2539546 C CA 2539546C CA 2539546 A CA2539546 A CA 2539546A CA 2539546 A CA2539546 A CA 2539546A CA 2539546 C CA2539546 C CA 2539546C
Authority
CA
Canada
Prior art keywords
oxo
carbonitrile
dihydroisoquinoline
methoxy
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2539546A
Other languages
English (en)
French (fr)
Other versions
CA2539546A1 (en
Inventor
Richard Isaacs
Christopher J. Dinsmore
B. Wesley Trotter
Nigel Liverton
Douglas C. Beshore
Nathan R. Kett
Charles J. Mcintyre
Kausik K. Nanda
David A. Claremon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2539546A1 publication Critical patent/CA2539546A1/en
Application granted granted Critical
Publication of CA2539546C publication Critical patent/CA2539546C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2539546A 2003-09-23 2004-09-22 Isoquinoline potassium channel inhibitors Expired - Fee Related CA2539546C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50521603P 2003-09-23 2003-09-23
US60/505,216 2003-09-23
PCT/US2004/030945 WO2005030729A1 (en) 2003-09-23 2004-09-22 Isoquinoline potassium channel inhibitors

Publications (2)

Publication Number Publication Date
CA2539546A1 CA2539546A1 (en) 2005-04-07
CA2539546C true CA2539546C (en) 2010-07-13

Family

ID=34392992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2539546A Expired - Fee Related CA2539546C (en) 2003-09-23 2004-09-22 Isoquinoline potassium channel inhibitors

Country Status (7)

Country Link
US (1) US7763614B2 (enExample)
EP (1) EP1667981A4 (enExample)
JP (1) JP4824563B2 (enExample)
CN (1) CN1856477A (enExample)
AU (1) AU2004276268B2 (enExample)
CA (1) CA2539546C (enExample)
WO (1) WO2005030729A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709476B2 (en) * 2003-09-23 2010-05-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
CA2539729C (en) * 2003-09-23 2010-09-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2539541C (en) * 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2006015159A2 (en) 2004-07-29 2006-02-09 Merck & Co., Inc. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
EP2376453B1 (en) * 2008-12-11 2019-11-20 VIIV Healthcare Company Intermediates for carbamoylpyridone hiv integrase inhibitors
AU2009335843A1 (en) * 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
GB0909671D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
CN103922952A (zh) * 2014-05-07 2014-07-16 宁夏宝马药业有限公司 用羟基乙腈制取环丙基甘氨酸的方法
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MX2022004144A (es) * 2019-10-07 2022-06-14 De Shaw Res Llc Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
AU2020362118A1 (en) * 2019-10-07 2022-04-21 D.E. Shaw Research, Llc Aryl heterobicyclic compounds as Kv1.3 potassium shaker channel blockers
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287032C (enExample)
DD287032A5 (de) * 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
TW241258B (enExample) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
NO179904C (no) 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
DE60132606T2 (de) 2000-09-20 2009-02-19 Merck & Co., Inc. Isochinolinone als kalium-kanal-inhibitoren
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
US7709476B2 (en) * 2003-09-23 2010-05-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
CA2539541C (en) * 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2539729C (en) * 2003-09-23 2010-09-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors

Also Published As

Publication number Publication date
WO2005030729A1 (en) 2005-04-07
CA2539546A1 (en) 2005-04-07
US20070054892A1 (en) 2007-03-08
JP2007506749A (ja) 2007-03-22
EP1667981A1 (en) 2006-06-14
AU2004276268A1 (en) 2005-04-07
EP1667981A4 (en) 2008-08-13
US7763614B2 (en) 2010-07-27
JP4824563B2 (ja) 2011-11-30
CN1856477A (zh) 2006-11-01
AU2004276268B2 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
CA2539546C (en) Isoquinoline potassium channel inhibitors
CA2539707C (en) Quinoline potassium channel inhibitors
CA2539479C (en) Isoquinoline potassium channel inhibitors
AU2004289186B2 (en) Isoquinolinone potassium channel inhibitors
CA2539541C (en) Isoquinolinone potassium channel inhibitors
CA2539476C (en) Quinazoline potassium channel inhibitors
CA2539729C (en) Isoquinolinone potassium channel inhibitors
CA2539760C (en) Quinoline potassium channel inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150922